Skip to main content

Table 1 Descriptive characteristics of HIV-infected adults on antiretroviral therapy by mortality and LTFU outcomes

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 MortalityLTFU
6 months12 months24 months36 months6 months12 months24 months36 months
n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)
Gender
 Female (n = 16182)304 (54.7)395 (55.2)519 (56.2)576 (56.1)1549 (63.2)2272 (64.7)3358 (65.6)4282 (65.9)
 Male (n = 7708)252 (45.3)320 (44.8)405 (43.8)451 (43.9)902 (36.8)1241 (35.3)1759 (34.4)2217 (34.1)
 Total (n = 23890)        
Age
 20–35 (n = 10827)229 (41.2)281 (39.3)370 (40.0)414 (40.3)1203 (49.1)1797 (51.2)2675 (52.3)3369 (51.8)
 36–50 (n = 10629)255 (45.9)336 (47.0)425 (46.0)470 (45.8)1016 (41.5)1404 (40.0)2001 (39.1)2558 (39.4)
 51+ (n = 2434)72 (12.9)98 (13.7)129 (14.0)143 (13.9)232 (9.5)312 (8.9)441 (8.6)572 (8.8)
 Total (n = 23890)        
Marital Status
 Divorced (n = 3923)91 (17.7)126 (19.0)165 (19.1)178 (18.8)451 (21.0)644 (20.6)906 (19.7)1193 (20.3)
 Married (n = 11143)203 (39.6)273 (41.1)353 (41.0)385 (40.7)963 (44.7)1422 (45.5)2128 (46.4)2738 (46.7)
 Single (n = 4091)146 (28.5)179 (27.0)224 (26.0)251 (26.5)487 (22.6)699 (22.4)1014 (22.1)1235 (21.1)
 Widowed (n = 2975)73 (14.2)86 (13.0)120 (13.9)133 (14.0)251 (11.7)359 (11.5)541 (11.8)698 (11.9)
 Total (n = 22132)        
BMI
 < 18.5 (n = 3466)123 (49.2)148 (47.6)191 (46.8)210 (47.1)326 (40.3)441 (36.7)633 (33.0)819 (30.9)
 18.5–24.9 (n = 6887)110 (44.0)137 (44.1)181 (44.4)197 (44.2)399 (49.4)623 (51.9)1027 (53.6)1437 (54.3)
 25–29.9 (n = 1708)13 (5.2)19 (6.1)26 (6.4)29 (6.5)59 (7.3)96 (8)178 (9.3)264 (10.0)
 30+ (n = 807)4 (1.6)7 (2.3)10 (2.5)10 (2.2)24 (3.0)41 (3.4)79 (4.1)128 (4.8)
 Total (n = 12868)        
Baseline CD4
 0–250 (n = 15483)387 (91.7)491 (90.9)648 (91.7)715 (90.9)1615 (86.5)2343 (85.9)3357 (83.5)4275 (83.1)
 251–500 (n = 3611)34 (8.1)48 (8.9)56 (7.9)69 (8.8)236 (12.6)366 (13.4)630 (15.7)830 (16.1)
 Above 500 (n = 124)1 (0.2)1 (0.2)3 (0.4)3 (0.4)15 (0.8)19 (0.7)33 (0.8)39 (0.8)
 Total (n = 19218)        
Regimen started
 ABC-based (n = 370)8 (1.4)8 (1.1)9 (1.0)9 (0.9)82 (3.3)113 (3.2)148 (2.9)166 (2.6)
 AZT-based (n = 4465)102 (18.3)130 (18.2)156 (16.9)167 (16.3)371 (15.1)544 (15.5)827 (16.2)1102 (17.0)
 D4T-based (n = 12949)360 (64.7)466 (65.2)613 (66.3)690 (67.2)1556 (63.5)2178 (62.0)3062 (59.8)3728 (57.4)
 TDF-based (n = 6106)86 (15.5)111 (15.5)146 (15.8)161 (15.7)442 (18.0)678 (19.3)1080 (21.1)1503 (23.1)
 Total (n = 23890)        
WHO clinical stage at ART initiation
 Stage I (n = 3310)30 (6.4)40 (6.7)53 (6.9)63 (7.5)231 (13.5)354 (14.2)572 (15.5)763 (16.1)
 Stage II (n = 6800)104 (22.3)136 (22.6)183 (23.8)208 (24.7)535 (31.4)832 (33.4)1267 (34.3)1661 (34.9)
 Stage III (n = 7282)249 (53.3)322 (53.6)404 (52.5)436 (51.8)801 (47.0)1132 (45.5)1632 (44.1)2047 (43.1)
 Stage IV (n = 994)84 (18.0)103 (17.1)129 (16.8)135 (16.0)138 (8.1)171 (6.9)226 (6.1)282 (5.9)
 Total (n = 18386)        
Dead556 (2.3)715 (3.0)924 (3.9)1027 (4.3)    
LTFU    2451 (10.3)3513 (14.7)5117 (21.4)6499 (27.2)